CO4940454A1 - Nuevo metodo de tratamiento - Google Patents

Nuevo metodo de tratamiento

Info

Publication number
CO4940454A1
CO4940454A1 CO98034654A CO98034654A CO4940454A1 CO 4940454 A1 CO4940454 A1 CO 4940454A1 CO 98034654 A CO98034654 A CO 98034654A CO 98034654 A CO98034654 A CO 98034654A CO 4940454 A1 CO4940454 A1 CO 4940454A1
Authority
CO
Colombia
Prior art keywords
treatment
insulin
mammal
new method
compound
Prior art date
Application number
CO98034654A
Other languages
English (en)
Spanish (es)
Inventor
Smith Stephen Alistair
Original Assignee
Smithkline Beecham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham filed Critical Smithkline Beecham
Publication of CO4940454A1 publication Critical patent/CO4940454A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
CO98034654A 1997-06-18 1998-06-18 Nuevo metodo de tratamiento CO4940454A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9712866.4A GB9712866D0 (en) 1997-06-18 1997-06-18 Novel method of treatment

Publications (1)

Publication Number Publication Date
CO4940454A1 true CO4940454A1 (es) 2000-07-24

Family

ID=10814527

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98034654A CO4940454A1 (es) 1997-06-18 1998-06-18 Nuevo metodo de tratamiento

Country Status (30)

Country Link
EP (1) EP0999837A1 (fr)
JP (1) JP2002504138A (fr)
KR (1) KR20010013843A (fr)
CN (1) CN1133431C (fr)
AP (1) AP1287A (fr)
AR (2) AR015894A1 (fr)
AU (1) AU8216398A (fr)
BG (1) BG104059A (fr)
BR (1) BR9810444A (fr)
CA (1) CA2294141A1 (fr)
CO (1) CO4940454A1 (fr)
DZ (1) DZ2521A1 (fr)
EA (1) EA004800B1 (fr)
GB (1) GB9712866D0 (fr)
HU (1) HUP0003260A3 (fr)
ID (1) ID23951A (fr)
IL (1) IL133143A0 (fr)
IN (1) IN189723B (fr)
MA (1) MA26511A1 (fr)
NO (1) NO996265L (fr)
OA (1) OA11517A (fr)
PE (1) PE104499A1 (fr)
PL (1) PL343123A1 (fr)
SK (1) SK179399A3 (fr)
TR (1) TR199903095T2 (fr)
TW (1) TW587937B (fr)
UA (1) UA70299C2 (fr)
UY (1) UY25050A1 (fr)
WO (1) WO1998057636A1 (fr)
ZA (1) ZA985237B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
BR0009934A (pt) 1999-04-23 2002-06-04 Smithkline Beecham Plc Produto farmacêutico
EP1133312B8 (fr) * 1999-06-21 2007-10-17 Eli Lilly And Company Utilisation combinee de thiazolidinediones et de peptide-1 de type glucagone et d'agonistes de ces derniers pour traiter diabetes non insulino-dependant.
WO2001000223A2 (fr) * 1999-06-25 2001-01-04 Minimed Inc. Therapie anti diabete a agents multiples
US6468507B1 (en) * 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
GB0023970D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
AU2002248464A1 (en) 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
US6531461B1 (en) 2001-06-04 2003-03-11 Louis Obyo Obyo Nelson Medicament for the treatment of diabetes
WO2002100396A1 (fr) * 2001-06-07 2002-12-19 Wyeth Combinaison d'un inhibiteur de la ptpase et d'un agent thiazolidinedione
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
AU2003276234B2 (en) 2002-11-08 2007-04-19 F. Hoffmann-La Roche Ag Substituted 4-alkoxyoxazol derivatives as PPAR agonists
US7264813B2 (en) * 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
CN102389427A (zh) * 2011-10-10 2012-03-28 成都恒瑞制药有限公司 含有罗格列酮和盐酸西替利嗪的固体口服制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007694A1 (fr) * 1993-09-15 1995-03-23 Sankyo Company, Limited Utilisation de thiazolidinediones pour prevenir ou retarder l'apparition du diabete sucre non insulinodependant
WO1997005875A2 (fr) * 1995-08-10 1997-02-20 Warner-Lambert Company Procede permettant de reduire la quantite d'insuline exogene administree a un patient souffrant de diabete sucre non-insulinodependant
AU725998B2 (en) * 1995-09-18 2000-10-26 Eisai R&D Management Co., Ltd. Treating NIDDM with RXR agonists

Also Published As

Publication number Publication date
AU8216398A (en) 1999-01-04
NO996265D0 (no) 1999-12-17
WO1998057636A1 (fr) 1998-12-23
EA004800B1 (ru) 2004-08-26
AR012997A1 (es) 2000-11-22
KR20010013843A (ko) 2001-02-26
IL133143A0 (en) 2001-03-19
CN1133431C (zh) 2004-01-07
TW587937B (en) 2004-05-21
SK179399A3 (en) 2000-11-07
EP0999837A1 (fr) 2000-05-17
JP2002504138A (ja) 2002-02-05
AR015894A1 (es) 2001-05-30
CN1260715A (zh) 2000-07-19
OA11517A (en) 2004-02-04
IN189723B (fr) 2003-04-19
AP9901718A0 (en) 1999-12-31
UY25050A1 (es) 2000-09-29
DZ2521A1 (fr) 2003-02-08
ZA985237B (en) 2000-02-17
MA26511A1 (fr) 2004-12-20
TR199903095T2 (xx) 2000-08-21
NO996265L (no) 1999-12-17
AP1287A (en) 2004-06-26
BG104059A (en) 2000-10-31
HUP0003260A2 (hu) 2001-05-28
ID23951A (id) 2000-06-08
PL343123A1 (en) 2001-07-30
CA2294141A1 (fr) 1998-12-23
EA200000042A1 (ru) 2000-08-28
BR9810444A (pt) 2000-09-05
HUP0003260A3 (en) 2001-12-28
UA70299C2 (en) 2004-10-15
PE104499A1 (es) 2000-01-13
GB9712866D0 (en) 1997-08-20

Similar Documents

Publication Publication Date Title
CO4940454A1 (es) Nuevo metodo de tratamiento
MY129897A (en) Use of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2, 4-dione and metformin for the treatment of diabetes mellitus
YU37301A (sh) Farmaceutski preparat za modifikovano oslobađanje sensitizera insulina i drugog antidijabetskog agensa
EA200000139A1 (ru) Лечение диабета тиазолидиндионом, средством, стимулирующим секрецию инсулина, и дигуанидом
MY135973A (en) Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative
AR008198A1 (es) Procedimiento para preparar una composicion farmaceutica de 5-[4-[2-(n- metil-n-(2-piridil)amino)etoxi]bencil]tiazolin-2,4-diona
PE108199A1 (es) Composicion farmaceutica de tiazolidindiona y sulfonilurea
AR016350A1 (es) Uso de un sensibilizador a insulina, un secretagogo de insulina y un agente antihiperglucemico inhibidor de alfa-glucosidasa para prepararmedicamentos
AR016768A1 (es) COMPOSICIoN FARMACÉUTICA DE 5-(4- (2-(N-METIL-N-(2-PIRIDIL) AMINO)ETOXI)BENCIL)TIAZOLIDIN-2-4-DIONA Y UN SECRETAGOGO DE INSULINA Y USO DE LA MISMA PARA PREPARACIoN DE MEDICAMENTOS
AR013352A1 (es) Uso de un sensibilizador a insulina y un agente antihiperglucemico para la preparacion de un medicamento para el tratamiento de la diabetes mellitus ycondiciones asociadas a la misma y una composicion farmaceutica.
UY25801A1 (es) Procedimiento para preparar composiciones para el tratamiento de diabetes.
CO5150180A1 (es) Nueva composicion y uso liberacion modificada
ECSP982542A (es) Nuevo metodo de tratamiento iii
ECSP982593A (es) Nuevo metodo de tratamiento vi
EA200300423A1 (ru) Производное тиазолидиндиона и его применение в качестве противодиабетического лекарственного средства
ECSP982591A (es) Nuevo metodo de tratamiento iv
ECSP982534A (es) Nuevo metodo de tratamiento
ECSP982592A (es) Nuevo metodo de tratamiento v
ECSP982535A (es) Nuevo metodo de tratamiento (i)